Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection.
(2012) In New England Journal of Medicine 367(3). p.224-232- Abstract
- BACKGROUND:
Progressive immune dysfunction and the acquired immunodeficiency syndrome (AIDS) develop in most persons with untreated infection with human immunodeficiency virus type 1 (HIV-1) but in only approximately 20 to 30% of persons infected with HIV type 2 (HIV-2); among persons infected with both types, the natural history of disease progression is poorly understood.
METHODS:
We analyzed data from 223 participants who were infected with HIV-1 after enrollment (with either HIV-1 infection alone or HIV-1 and HIV-2 infection) in a cohort with a long follow-up duration (approximately 20 years), according to whether HIV-2 infection occurred first, the time to the development of AIDS (time to AIDS),... (More) - BACKGROUND:
Progressive immune dysfunction and the acquired immunodeficiency syndrome (AIDS) develop in most persons with untreated infection with human immunodeficiency virus type 1 (HIV-1) but in only approximately 20 to 30% of persons infected with HIV type 2 (HIV-2); among persons infected with both types, the natural history of disease progression is poorly understood.
METHODS:
We analyzed data from 223 participants who were infected with HIV-1 after enrollment (with either HIV-1 infection alone or HIV-1 and HIV-2 infection) in a cohort with a long follow-up duration (approximately 20 years), according to whether HIV-2 infection occurred first, the time to the development of AIDS (time to AIDS), CD4+ and CD8+ T-cell counts, and measures of viral evolution.
RESULTS:
The median time to AIDS was 104 months (95% confidence interval [CI], 75 to 133) in participants with dual infection and 68 months (95% CI, 60 to 76) in participants infected with HIV-1 only (P=0.003). CD4+ T-cell levels were higher and CD8+ T-cell levels increased at a lower rate among participants with dual infection, reflecting slower disease progression. Participants with dual infection with HIV-2 infection preceding HIV-1 infection had the longest time to AIDS and highest levels of CD4+ T-cell counts. HIV-1 genetic diversity was significantly lower in participants with dual infections than in those with HIV-1 infection alone at similar time points after infection.
CONCLUSIONS:
Our results suggest that HIV-1 disease progression is inhibited by concomitant HIV-2 infection and that dual infection is associated with slower disease progression. The slower rate of disease progression was most evident in participants with dual infection in whom HIV-2 infection preceded HIV-1 infection. These findings could have implications for the development of HIV-1 vaccines and therapeutics. (Funded by the Swedish International Development Cooperation Agency-Swedish Agency for Research Cooperation with Developing Countries and others.). (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2966972
- author
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- HIV Infections: immunology, HIV Infections: virology, HIV-1: genetics, HIV-1: isolation & purification
- in
- New England Journal of Medicine
- volume
- 367
- issue
- 3
- pages
- 224 - 232
- publisher
- Massachusetts Medical Society
- external identifiers
-
- wos:000306522900006
- pmid:22808957
- scopus:84863993899
- pmid:22808957
- ISSN
- 0028-4793
- DOI
- 10.1056/NEJMoa1113244
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Molecular Virology (013212007), Infectious Diseases Research Unit (013242010), Oncology, MV (013035000), Division of Medical Microbiology (013250400), Division of Infection Medicine (SUS) (013008000)
- id
- 93e332fa-fbcb-43d3-a1cb-2976723f8224 (old id 2966972)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/22808957?dopt=Abstract
- date added to LUP
- 2016-04-01 10:13:25
- date last changed
- 2022-04-19 23:52:14
@article{93e332fa-fbcb-43d3-a1cb-2976723f8224, abstract = {{BACKGROUND:<br/><br> Progressive immune dysfunction and the acquired immunodeficiency syndrome (AIDS) develop in most persons with untreated infection with human immunodeficiency virus type 1 (HIV-1) but in only approximately 20 to 30% of persons infected with HIV type 2 (HIV-2); among persons infected with both types, the natural history of disease progression is poorly understood.<br/><br> <br/><br> METHODS:<br/><br> We analyzed data from 223 participants who were infected with HIV-1 after enrollment (with either HIV-1 infection alone or HIV-1 and HIV-2 infection) in a cohort with a long follow-up duration (approximately 20 years), according to whether HIV-2 infection occurred first, the time to the development of AIDS (time to AIDS), CD4+ and CD8+ T-cell counts, and measures of viral evolution.<br/><br> <br/><br> RESULTS:<br/><br> The median time to AIDS was 104 months (95% confidence interval [CI], 75 to 133) in participants with dual infection and 68 months (95% CI, 60 to 76) in participants infected with HIV-1 only (P=0.003). CD4+ T-cell levels were higher and CD8+ T-cell levels increased at a lower rate among participants with dual infection, reflecting slower disease progression. Participants with dual infection with HIV-2 infection preceding HIV-1 infection had the longest time to AIDS and highest levels of CD4+ T-cell counts. HIV-1 genetic diversity was significantly lower in participants with dual infections than in those with HIV-1 infection alone at similar time points after infection.<br/><br> <br/><br> CONCLUSIONS:<br/><br> Our results suggest that HIV-1 disease progression is inhibited by concomitant HIV-2 infection and that dual infection is associated with slower disease progression. The slower rate of disease progression was most evident in participants with dual infection in whom HIV-2 infection preceded HIV-1 infection. These findings could have implications for the development of HIV-1 vaccines and therapeutics. (Funded by the Swedish International Development Cooperation Agency-Swedish Agency for Research Cooperation with Developing Countries and others.).}}, author = {{Esbjörnsson, Joakim and Månsson, Fredrik and Kvist, Anders and Isberg, Per-Erik and Nowroozalizadeh, Salma and Biague, Antonio J and da Silva, Zacarias J and Jansson, Marianne and Fenyö, Eva Maria and Norrgren, Hans and Medstrand, Patrik}}, issn = {{0028-4793}}, keywords = {{HIV Infections: immunology; HIV Infections: virology; HIV-1: genetics; HIV-1: isolation & purification}}, language = {{eng}}, number = {{3}}, pages = {{224--232}}, publisher = {{Massachusetts Medical Society}}, series = {{New England Journal of Medicine}}, title = {{Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection.}}, url = {{http://dx.doi.org/10.1056/NEJMoa1113244}}, doi = {{10.1056/NEJMoa1113244}}, volume = {{367}}, year = {{2012}}, }